263 related articles for article (PubMed ID: 24312219)
1. Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy.
Fierro-Monti I; Echeverria P; Racle J; Hernandez C; Picard D; Quadroni M
PLoS One; 2013; 8(11):e80425. PubMed ID: 24312219
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibition induces both protein-specific and global changes in the ubiquitinome.
Quadroni M; Potts A; Waridel P
J Proteomics; 2015 Apr; 120():215-29. PubMed ID: 25782750
[TBL] [Abstract][Full Text] [Related]
3. A novel pulse-chase SILAC strategy measures changes in protein decay and synthesis rates induced by perturbation of proteostasis with an Hsp90 inhibitor.
Fierro-Monti I; Racle J; Hernandez C; Waridel P; Hatzimanikatis V; Quadroni M
PLoS One; 2013; 8(11):e80423. PubMed ID: 24312217
[TBL] [Abstract][Full Text] [Related]
4. Systematic identification of the HSP90 candidate regulated proteome.
Wu Z; Gholami AM; Kuster B
Mol Cell Proteomics; 2012 Jun; 11(6):M111.016675. PubMed ID: 22337586
[TBL] [Abstract][Full Text] [Related]
5. The expanding proteome of the molecular chaperone HSP90.
Samant RS; Clarke PA; Workman P
Cell Cycle; 2012 Apr; 11(7):1301-8. PubMed ID: 22421145
[TBL] [Abstract][Full Text] [Related]
6. Native Size-Exclusion Chromatography-Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global Changes.
Samant RS; Batista S; Larance M; Ozer B; Milton CI; Bludau I; Wu E; Biggins L; Andrews S; Hervieu A; Johnston HE; Al-Lazikhani B; Lamond AI; Clarke PA; Workman P
Mol Cell Proteomics; 2023 Feb; 22(2):100485. PubMed ID: 36549590
[TBL] [Abstract][Full Text] [Related]
7. The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.
Woodford MR; Dunn DM; Blanden AR; Capriotti D; Loiselle D; Prodromou C; Panaretou B; Hughes PF; Smith A; Ackerman W; Haystead TA; Loh SN; Bourboulia D; Schmidt LS; Marston Linehan W; Bratslavsky G; Mollapour M
Nat Commun; 2016 Jun; 7():12037. PubMed ID: 27353360
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
9. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
10. Quantitative proteomics of the yeast Hsp70/Hsp90 interactomes during DNA damage reveal chaperone-dependent regulation of ribonucleotide reductase.
Truman AW; Kristjansdottir K; Wolfgeher D; Ricco N; Mayampurath A; Volchenboum SL; Clotet J; Kron SJ
J Proteomics; 2015 Jan; 112():285-300. PubMed ID: 25452130
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain.
Terracciano S; Russo A; Chini MG; Vaccaro MC; Potenza M; Vassallo A; Riccio R; Bifulco G; Bruno I
Sci Rep; 2018 Jan; 8(1):1709. PubMed ID: 29374167
[TBL] [Abstract][Full Text] [Related]
12. Proteomic interrogation of HSP90 and insights for medical research.
Weidenauer L; Wang T; Joshi S; Chiosis G; Quadroni MR
Expert Rev Proteomics; 2017 Dec; 14(12):1105-1117. PubMed ID: 28990809
[TBL] [Abstract][Full Text] [Related]
13. Investigation of Cellular Response to the HSP90 Inhibition in Human Cells Through Thermal Proteome Profiling.
Yin K; Wu R
Mol Cell Proteomics; 2023 Jun; 22(6):100560. PubMed ID: 37119972
[TBL] [Abstract][Full Text] [Related]
14. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
Isaacs JS
Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
[TBL] [Abstract][Full Text] [Related]
15. [Impact of HSP90 Inhibition on Viability and Cell Cycle in Relation to p53 Status].
Pastorek M; Müller P; Vojtěšek B
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):40-45. PubMed ID: 27846719
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics.
Haupt A; Joberty G; Bantscheff M; Fröhlich H; Stehr H; Schweiger MR; Fischer A; Kerick M; Boerno ST; Dahl A; Lappe M; Lehrach H; Gonzalez C; Drewes G; Lange BM
BMC Cancer; 2012 Jan; 12():38. PubMed ID: 22277058
[TBL] [Abstract][Full Text] [Related]
18. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
19. Detecting the Potential Pharmacological Synergy of Drug Combination by Viability Assays In Vitro.
Gibbs BK; Sourbier C
Methods Mol Biol; 2018; 1709():129-137. PubMed ID: 29177656
[TBL] [Abstract][Full Text] [Related]
20. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
Moulick K; Ahn JH; Zong H; Rodina A; Cerchietti L; Gomes DaGama EM; Caldas-Lopes E; Beebe K; Perna F; Hatzi K; Vu LP; Zhao X; Zatorska D; Taldone T; Smith-Jones P; Alpaugh M; Gross SS; Pillarsetty N; Ku T; Lewis JS; Larson SM; Levine R; Erdjument-Bromage H; Guzman ML; Nimer SD; Melnick A; Neckers L; Chiosis G
Nat Chem Biol; 2011 Sep; 7(11):818-26. PubMed ID: 21946277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
